Biopharmaceutical company H. Lundbeck A/S (XCSE: HLUN A) reported on Wednesday that it will present new clinical data from its migraine portfolio at the European Academy of Neurology (EAN) Congress 2026 in Geneva, highlighting both approved and investigational therapies, including Vyepti (eptinezumab) and bocunebart.

The programme includes five presentations covering patient-centred outcomes for eptinezumab as well as Phase IIb PROCEED primary data for bocunebart, an investigational monoclonal antibody targeting the PACAP pathway in migraine prevention. The data underscore Lundbeck's dual strategy of optimising existing therapies while advancing next-generation treatments for patients with persistent unmet needs.

Eptinezumab analyses from the SUNRISE and RESOLUTION trials will assess outcomes beyond migraine frequency, including acute medication use, psychological wellbeing, anxiety and depression symptoms, workplace productivity and activity impairment in chronic migraine populations, including patients with medication-overuse headache.

Bocunebart data from the PROCEED study will provide further insight into PACAP pathway inhibition as a novel preventive approach in patients with prior treatment failures, with Phase IIb results previously meeting the primary endpoint.

Lundbeck said the EAN 2026 presentations reinforce its focus on addressing the broader clinical and functional burden of migraine, which remains a leading cause of disability globally, while advancing differentiated therapeutic approaches across its pipeline.